Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy
1997

Carbogen and Nicotinamide for Bladder Cancer Treatment

Sample size: 30 publication Evidence: moderate

Author Information

Author(s): PJ Hoskin, Ml Saunders, H Phillips, H Cladd, MEB Powell, K Goodchild, MR Stratford, A Rojas

Primary Institution: Marie Curie Research Wing, Mount Vernon Hospital

Hypothesis

Can carbogen and nicotinamide improve the effectiveness of radical radiotherapy for bladder cancer?

Conclusion

Carbogen and nicotinamide may enhance the results of daily fractionated radiotherapy in bladder cancer, but further evaluation is needed.

Supporting Evidence

  • Complete response rates at 6 months were 100% for nicotinamide alone, 90% for carbogen alone, and 70% for the combination.
  • No excess bowel or bladder morbidity was observed during the study.
  • The study suggests that compliance with nicotinamide may correlate with better treatment outcomes.

Takeaway

This study tested two drugs, carbogen and nicotinamide, to see if they help treat bladder cancer better when combined with radiation therapy.

Methodology

Patients were divided into three groups receiving different treatments: nicotinamide alone, carbogen alone, or both together, with standard radiation doses.

Limitations

The study had a small sample size and issues with patient compliance to nicotinamide treatment.

Participant Demographics

{"total":30,"age":{"nicotinamide":66,"carbogen":69,"nicotinamide_and_carbogen":69},"gender":{"nicotinamide":"9:1","carbogen":"10:0","nicotinamide_and_carbogen":"8:2"}}

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication